These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 3898289)

  • 1. Thymopentin: stability considerations and potency by various routes of administration.
    Audhya TK; Goldstein G
    Surv Immunol Res; 1985; 4 Suppl 1():17-23. PubMed ID: 3898289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy of various routes of administration of thymopentin (TP-5) with consideration of degradative mechanisms.
    Audhya T; Goldstein G
    Int J Pept Protein Res; 1983 Aug; 22(2):187-93. PubMed ID: 6352534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymopentin (TP-5) potency in vivo is enhanced by slow infusion.
    Audhya T; Goldstein G
    Int J Pept Protein Res; 1983 Nov; 22(5):568-72. PubMed ID: 6360927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short in vitro half-life of thymopoietin32--36 pentapeptide in human plasma.
    Tischio JP; Patrick JE; Weintraub HS; Chasin M; Goldstein G
    Int J Pept Protein Res; 1979; 14(5):479-84. PubMed ID: 395119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical response to therapy with thymopoietin pentapeptide (TP-5) in rheumatoid arthritis.
    Veys EM; Huskisson EC; Rosenthal M; Vischer TL; Mielants H; Thrower PA; Scott J; Ott H; Scheijgrond H; Symoens J
    Ann Rheum Dis; 1982 Oct; 41(5):441-3. PubMed ID: 6751241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymopoietin pentapeptide (thymopentin, TP-5) in the treatment of rheumatoid arthritis. A compilation of several short- and longterm clinical studies.
    Veys EM; Mielants H; Verbruggen G; Spiro T; Newdeck E; Power D; Goldstein G
    J Rheumatol; 1984 Aug; 11(4):462-6. PubMed ID: 6384507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologically active analogs of thymopentin with enhanced enzymatic stability.
    Heavner GA; Kroon DJ; Audhya T; Goldstein G
    Peptides; 1986; 7(6):1015-9. PubMed ID: 3031628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Some observations on various dose regimens of thymopentin treatment in rheumatoid arthritis.
    Molin L; Schmid F; Bolla K
    Surv Immunol Res; 1985; 4 Suppl 1():76-80. PubMed ID: 3898296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymopoietin to thymopentin: experimental studies.
    Goldstein G; Audhya TK
    Surv Immunol Res; 1985; 4 Suppl 1():1-10. PubMed ID: 2994196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural requirements for the biological activity of thymopentin analogs.
    Heavner GA; Audhya T; Kroon D; Goldstein G
    Arch Biochem Biophys; 1985 Oct; 242(1):248-55. PubMed ID: 2996431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arg-Lys-Asp-Val-Tyr (thymopentin) accelerates the cholinergic-induced inactivation (desensitization) of reconstituted nicotinic receptor.
    Ochoa EL; Medrano S; de Carlin MC; Dilonardo AM
    Cell Mol Neurobiol; 1988 Sep; 8(3):325-31. PubMed ID: 3066488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of immune response in aged humans through different administration modes of thymopentin.
    Duchateau J; Servais G; Vreyens R; Delespesse G; Bolla K
    Surv Immunol Res; 1985; 4 Suppl 1():94-101. PubMed ID: 3898299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Degradation of thymopentin by human lymphocytes: evidence for aminopeptidase activity.
    Amoscato AA; Balasubramaniam A; Alexander JW; Babcock GF
    Biochim Biophys Acta; 1988 Jul; 955(2):164-74. PubMed ID: 3293664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cooperativity of thymopoietin 32-36 (the active site) and thymopoietin 38-45 in receptor binding.
    Audhya T; Heavner GA; Kroon DJ; Goldstein G
    Regul Pept; 1984 Oct; 9(3):155-64. PubMed ID: 6098937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First observations on high-dosed and long-term thymopentin treatment in active rheumatoid arthritis.
    Molin L; Schmid F; Bolla K
    Int J Clin Pharmacol Res; 1984; 4(6):445-9. PubMed ID: 6398313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymopentin as adjuvant to hepatitis B vaccination. Results from three double-blind studies.
    Grob PJ; Binswanger U; Blumberg A; Gloor HJ; Hany A; Herwig W; Iselin H; Zàruba K; Bolla K
    Surv Immunol Res; 1985; 4 Suppl 1():107-15. PubMed ID: 3898281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Telethermographic evaluation of the intra-articular administration of thymopentin in rheumatoid arthritis of the knee].
    Pappalardo A; Sallì L; Campisi D; Scalici G; Di Marco C; Martorana U
    Clin Ter; 1989 Mar; 128(5):321-7. PubMed ID: 2524320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interim results on the clinical effects of i.v. administered thymopentin in active rheumatoid arthritis.
    Malaise M; Franchimont P; Hauwaert C; Danneskiold-Samsoe B; Gross D; Gerber H; Gerschpacher H; Bolla K
    Int J Clin Pharmacol Res; 1984; 4(6):451-7. PubMed ID: 6398314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymopentin in the treatment of alopecia areata.
    Orecchia G
    Dermatologica; 1989; 178(4):231. PubMed ID: 2670621
    [No Abstract]   [Full Text] [Related]  

  • 20. [Conformation states of thymopentin and its synthetic analogs].
    Akhmedov NA; Khalilova NM; Popov EM
    Mol Biol (Mosk); 1987; 21(1):159-63. PubMed ID: 3553894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.